MedTrace Logo

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

NCT07675967 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2026-06-30

No results posted yet for this study

Summary

The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers.

The study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs).

Ultimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.

Conditions

  • Lung Cancer (Diagnosis)
  • Osteochondroma
  • Spitz Nevus
  • Solid Cancers
  • Breast Cancer
  • Gastric (Stomach) Cancer
  • Colorectal (Colon or Rectal) Cancer
  • Sarcoma
  • Ovarian Adenocarcinoma
  • Uterine Adenocarcinoma
  • Endometrial Adenocarcinoma
  • Esophageal Adenocarcinoma
  • Head and Neck Cancer
  • Therapy-Related Acute Myeloid Leukemia
  • Therapy-Related MDS
  • Clonal Hematopoiesis of Indeterminate Potential (CHIP)
  • Clonal Cytopenia of Undetermined Significance

Interventions

OTHER

Samples

Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues

Sponsors & Collaborators

Principal Investigators

  • Lachelle D Weeks, MD, PhD · Dana-Farber Cancer Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-04
Primary Completion
2028-06-30
Completion
2035-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07675967 on ClinicalTrials.gov